Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.

Giovanni Savettieri, Mancardi, Cottone, Bergamaschi, Sotgiu, Centonze, Gallo, Bellantonio, Vincenzo Brescia Brescia Morra, Millefiorini, Lugaresi, Trojano, Ghezzi, Capra, Pozzilli, Antonio Bertolotto, Marrosu, Tola, Montanari, Luigi M.E. GrimaldiDurelli, Provinciali, Gioacchino Tedeschi, Maria Pia Amato, Domenico Caputo, Comi

    Risultato della ricerca: Articlepeer review

    13 Citazioni (Scopus)

    Abstract

    Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relapsingremitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
    Lingua originaleEnglish
    pagine (da-a)351-358
    Numero di pagine8
    RivistaNeurological Sciences
    Volume32
    Stato di pubblicazionePublished - 2011

    All Science Journal Classification (ASJC) codes

    • Dermatology
    • Clinical Neurology
    • Psychiatry and Mental health

    Fingerprint Entra nei temi di ricerca di 'Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.'. Insieme formano una fingerprint unica.

    Cita questo